tapentadol Articles

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

16 December 2012

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity

21 March 2012

Johnson & Johnson’s Nucynta OKed by US FDA for moderate to severe chronic pain

30 August 2011

Grunenthal debuts novel severe pain drug Palexia SR in UK

16 May 2011

J&J’s tapentadol may significantly reduce pain intensity for diabetics with peripheral neuropathy

31 January 2011

Galapagos in deal with Johnson & Johnson unit for oncology target in 33.5 million-euro deal; US FDA delays J&J’s tapentadol ER

5 October 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end